Relay Therapeutics (NASDAQ:RLAY) Shares Up 8.4% – Time to Buy?

Relay Therapeutics, Inc. (NASDAQ:RLAY) was up 8.4% during mid-day trading on Tuesday . The company traded as high as $8.15 and last traded at $8.2280. Approximately 315,477 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 2,184,687 shares. The stock had previously closed at $7.59.

Relay Therapeutics News Summary

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Shares are trading up intraday, sitting above the 200‑day moving average—a technical signal some investors view as constructive. MarketBeat RLAY quote
• Neutral Sentiment: Despite the recent sales, insiders still hold large positions (many hundreds of thousands of shares), which reduces the likelihood of a meaningful shift in strategic control; the disclosures show percentage ownership declines but substantial remaining stakes. (See SEC filings linked below.)
• Negative Sentiment: CFO Thomas Catinazzo sold 1,695 shares at an average $8.45 on Jan. 28 (total ~$14.3k), and had also sold 13,820 shares at ~$7.62 on Jan. 27; these filings show a multi-day reduction in the CFO’s ownership. Catinazzo filings
• Negative Sentiment: Insider Peter Rahmer sold 1,354 shares at $8.45 (Jan. 28) and 11,684 shares at $7.62 (Jan. 27), reducing his stake by several percent—more insider selling that can weigh on sentiment. Rahmer filings
• Negative Sentiment: Insider Donald A. Bergstrom sold 2,686 shares at $8.45 and 18,895 shares at $7.62 across Jan. 27–28, cutting his position by ~4%. Large, clustered insider sales can amplify near‑term downward pressure. Bergstrom filings
• Negative Sentiment: Market commentary highlights recent weakness in RLAY (example: a note explaining a ~5.2% drop), which may reflect short‑term sentiment, sector dynamics, or news-driven selling; that coverage can push momentum lower even if fundamentals are unchanged. Why RLAY is down 5.18%

Wall Street Analysts Forecast Growth

Several analysts have commented on RLAY shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Wells Fargo & Company raised shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $6.00 to $13.00 in a research note on Friday, December 12th. Finally, Oppenheimer raised Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.57.

Relay Therapeutics Trading Up 0.8%

The company’s 50-day moving average is $7.96 and its 200 day moving average is $5.95. The stock has a market capitalization of $1.34 billion, a PE ratio of -4.41 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last issued its earnings results on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Sell-side analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insider Activity at Relay Therapeutics

In related news, insider Peter Rahmer sold 11,684 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the completion of the transaction, the insider owned 277,964 shares in the company, valued at $2,118,085.68. This represents a 4.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Donald A. Bergstrom sold 18,895 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the transaction, the insider directly owned 422,733 shares in the company, valued at approximately $3,221,225.46. This represents a 4.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 155,375 shares of company stock valued at $1,158,866. Insiders own 4.87% of the company’s stock.

Institutional Investors Weigh In On Relay Therapeutics

Institutional investors have recently modified their holdings of the company. Commodore Capital LP increased its stake in shares of Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after buying an additional 3,650,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Relay Therapeutics by 3.1% in the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after acquiring an additional 295,701 shares during the period. Bellevue Group AG raised its holdings in shares of Relay Therapeutics by 1.4% in the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock valued at $43,564,000 after buying an additional 114,740 shares during the last quarter. Geode Capital Management LLC lifted its position in Relay Therapeutics by 5.2% during the 2nd quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock worth $11,176,000 after acquiring an additional 159,548 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Relay Therapeutics by 14.6% during the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock worth $7,710,000 after purchasing an additional 374,491 shares during the period. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.